Growth Metrics

Tandem Diabetes Care (TNDM) Long-Term Debt Repayments (2013 - 2025)

Tandem Diabetes Care posted quarterly Long-Term Debt Repayments of -$40.8 million for Q4 2025, down 116.56% year-on-year from $246.1 million in Q4 2024, and down 200.0% on a QoQ basis from $40.8 million in Q2 2025.

Tandem Diabetes Care (TNDM) has 3 years of Long-Term Debt Repayments data on file, last reported at -$40.8 million in Q4 2025.

  • For the quarter ending Q4 2025, Long-Term Debt Repayments fell 116.56% year-over-year to -$40.8 million; the trailing twelve-month figure through Sep 2025 stood at $286.9 million (changed N/A YoY), and the FY2024 full-year result was $246.1 million, changed N/A from the prior year.
  • Long-Term Debt Repayments for Q4 2025 stood at -$40.8 million, down from $40.8 million in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $246.1 million in Q1 2024 and bottomed at -$246.1 million in Q3 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Repayments (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 1.42 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn 1.00 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn -
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn -
10 Tandem Diabetes Care 1.31 Bn 739.55 Mn 136.79 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 -40.76 Mn
Dec 31, 2025 -40.76 Mn
Jun 30, 2025 40.76 Mn
Jun 30, 2025 40.76 Mn
Dec 31, 2024 246.12 Mn
Dec 31, 2024 246.12 Mn
Sep 30, 2024 -246.12 Mn
Sep 30, 2024 -246.12 Mn
Mar 31, 2024 246.12 Mn
Mar 31, 2024 246.12 Mn
Dec 31, 2013 -323.00
Dec 31, 2013 -323.00
Mar 31, 2013 4.40 Mn
Mar 31, 2013 4.40 Mn